Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STOP360 Aminoglycoside Study
NCT05548283Phase 4Recruiting
- Start
- Apr 2023
- Primary completion
- May 2027
- Countries
- 2
01
Overview
Phase 4, randomised, open-label trial in cystic fibrosis (CF) (2 arms). Primary endpoints: Absolute Change in FEV1 % Predicted at 4 weeks and Incidence of Adverse Events at 6 weeks. Started Apr 2023; status: recruiting.
02
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT05548283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05548283.